1.1 	A bill for an act
1.2 	relating to health; modifying the medical cannabis program; allowing vaporization 
1.3 	of flower, dried leaves, or plant form; making changes to the definition of qualifying 
1.4 	medical condition;amending Minnesota Statutes 2018, section 152.22, subdivision 
1.5 	14; Minnesota Statutes 2019 Supplement, section 152.22, subdivision 6.
1.6 	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

1.7 	Section 1. Minnesota Statutes 2019 Supplement, section 152.22, subdivision 6, is amended 
1.8 	to read:
1.9 		Subd. 6.Medical cannabis. (a) "Medical cannabis" means any species of the genus 
1.10 	cannabis plant, or any mixture or preparation of them, including whole plant extracts and 
1.11 	resins, and is delivered in the form of:
1.12 	(1) liquid, including, but not limited to, oil;
1.13 	(2) pill;
1.14 	(3) vaporized delivery method with use of liquid or, oil but which does not require the 
1.15 	use of dried leaves or plant form, or raw cannabis; or
1.16 	(4) any other method, excluding smoking, approved by the commissioner.
1.17 	(b) This definition includes any part of the genus cannabis plant prior to being processed 
1.18 	into a form allowed under paragraph (a), that is possessed by a person while that person is 
1.19 	engaged in employment duties necessary to carry out a requirement under sections 152.22 
1.20 	to 152.37 for a registered manufacturer or a laboratory under contract with a registered 
1.21 	manufacturer. This definition also includes any hemp acquired by a manufacturer by a hemp 
1.22 	grower as permitted under section 152.29, subdivision 1, paragraph (b).

2.1 	Sec. 2. Minnesota Statutes 2018, section 152.22, subdivision 14, is amended to read:
2.2 		Subd. 14.Qualifying medical condition. "Qualifying medical condition" means a 
2.3 	diagnosis of any of the following conditions:
2.4 	(1) cancer, if the underlying condition or treatment produces one or more of the 
2.5 	following:;
2.6 	(i) severe or chronic pain;
2.7 	(ii) nausea or severe vomiting; or
2.8 	(iii) cachexia or severe wasting;
2.9 	(2) glaucoma;
2.10 	(3) human immunodeficiency virus or acquired immune deficiency syndrome;
2.11 	(4) Tourette's syndrome;
2.12 	(5) amyotrophic lateral sclerosis;
2.13 	(6) seizures, including those characteristic of epilepsy;
2.14 	(7) severe and persistent muscle spasms, including those characteristic of multiple 
2.15 	sclerosis;
2.16 	(8) inflammatory bowel disease, including Crohn's disease;
2.17 	(9) terminal illness, with a probable life expectancy of under one year, if the illness or 
2.18 	its treatment produces one or more of the following:; or
2.19 	(i) severe or chronic pain;
2.20 	(ii) nausea or severe vomiting; or
2.21 	(iii) cachexia or severe wasting; or
2.22 	(10) any other medical condition or its treatment approved by the commissioner.